Recently, the national health and Health Commission and the State Administration of traditional Chinese medicine jointly issued the New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth). In March 18th, a number of listed companies including Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) announced that the company’s related products were included in the New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth) (hereinafter referred to as the “new version of the diagnosis and treatment plan”).
Sinolink Securities Co.Ltd(600109) analyst Wang Ban said, “On the one hand, the adjustment of covid-19 diagnosis and treatment plan reflects China’s phased achievements in covid-19 detection, covid-19 specific drug research and approval, and the application of traditional Chinese medicine and other characteristic medical treatment. On the other hand, it also adapts to the changes of epidemic characteristics caused by mutant strains. At present, China has rich covid-19 oral medicine and covid-19 vaccine research and development pipelines. With the reading of clinical data of products under research and approval for listing, we will be more perfect Covid-19 control system. It is expected that with more and more evidence-based medical evidence showing the efficacy of traditional Chinese medicine in covid-19 treatment, it is expected to be popularized, and potential investment opportunities deserve attention. “
several products of listed companies were selected into the new diagnosis and treatment plan
With the introduction of the new diagnosis and treatment plan, many listed companies quickly announced that their products were listed.
According to the Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) bulletin, since the outbreak of COVID-19, Lianhua Qingwen capsules (granules) have been continuously recommended by the New Coronavirus pneumonia diagnosis and treatment plan (Trial fourth / five / six / seven / 8 edition) as the recommended period for Chinese medicine treatment. In the new version of the diagnosis and treatment plan released this time, in addition to continuing to list Lianhua Qingwen capsule (granule) as the recommended drug in the observation period of traditional Chinese medicine, it is also listed as the recommended drug for light and common types in the clinical treatment period (confirmed cases).
In addition to Lianhua Qingwen, there are Jiangsu Kanion Pharmaceutical Co.Ltd(600557) exclusive Reduning Injection included in the new diagnosis and treatment plan, which is listed as the recommended drug for severe and dangerous confirmed cases during clinical treatment; Huoxiang Zhengqi multi dosage form was listed as the recommended drug during the medical observation period Chongqing Taiji Industry (Group) Co.Ltd(600129) its Huoxiang Zhengqi oral liquid, Angong Niuhuang Pill, Suhexiang pill and dexamethasone sodium phosphate injection were also included in the new diagnosis and treatment plan, and were listed as recommended drugs for medical observation, critical or immunotherapy. It is worth mentioning that Chongqing Taiji Industry (Group) Co.Ltd(600129) of the Styrax pills had not been sold by the end of last year.
Bai Wenxi, chief economist of IPG China, said in an interview with Securities Daily: “The adjustment of covid-19 treatment plan makes it clear that traditional Chinese medicine will be included in the medical observation and clinical treatment period of the new treatment plan. On the one hand, it confirms the legitimacy and important position of traditional Chinese medicine in covid-19 treatment plan, and on the other hand, it also creates new market opportunities for relevant traditional Chinese medicine enterprises. After the adjustment, for enterprises included in the new diagnosis and treatment plan, some of their products will become recommended drugs, except that it will greatly increase In addition to increasing the market demand for these products and improving the company’s performance, it can also enhance the company’s influence in the pharmaceutical market. “
put forward higher requirements for relevant industrial chains
It is worth mentioning that the new diagnosis and treatment plan not only adjusts the relevant therapeutic drugs, but also “adds antigen detection as a supplement”.
With the disclosure of the new diagnosis and treatment plan, the approval of covid-19 antigen self-test products of many enterprises has accelerated. On the evening of March 17, the State Food and Drug Administration approved the registration application of covid-19 antigen self-test products of an enterprise. Since then, the number of covid-19 antigen self-test products approved in China has reached 14.
Sinolink Securities Co.Ltd(600109) analyst Wang Ban said: “The ninth edition of the diagnosis and treatment plan reflects the trend of graded treatment of mild and severe diseases, comprehensively considering the contradiction between the strong transmission ability of mutant strains and limited medical resources. With the continuous listing of covid-19 specific drugs, the release of covid-19 antigen detection and the increase in the proportion of enhanced needle vaccination, we expect that under the expectation of China’s anti epidemic normalization, it may have different effects on detection manufacturing drugs vaccines pharmacies and other sectors.”
\u3000\u3000 “Antigen self-test helps to grade and divert covid-19 detection, avoid the waste of medical resources caused by the unified use of nucleic acid, and alleviate the shortage of testing resources in the scenario of centralized testing demand. Assuming that our annual testing market is 8.5 billion yuan and the reagent market is about 5 billion yuan. With the implementation of follow-up policies, the market space is expected to open. Under the neutral assumption, the corresponding annual testing market is about 62 billion yuan and the reagent market is about 38 billion yuan.” Wang ban further said.
Wu WANYING, senior researcher of Tianyi digital economy think tank, said in an interview with Securities Daily: “The policy of supporting epidemic prevention and control, on the one hand, will create a more favorable production and operation environment for relevant industrial chain companies and contribute to the development of the company; on the other hand, it also puts forward higher requirements for the company’s business model, production efficiency and product standards. At the same time, under the trend of normalization of epidemic prevention and control, relevant companies should take the initiative to seize market opportunities and create leading technical standards through innovation, upgrading, transformation and other means Strengthen and expand enterprises and contribute to epidemic prevention and control. “
